Non-Myeloablative Allogeneic Transplantation

1. Front Matter

   Pages i-x

   PDF

2. Development of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

   • Januario E. Castro, Edward D. Ball

   Pages 1-37

3. Immunosuppression with Limited Toxicity: The Characteristics of Nucleoside Analogs and Anti-Lymphocyte Antibodies Used in Nonmyeloablative Hematopoietic Cell Transplantation

   • Asad Bashey

   Pages 39-49

4. Mobilization of Allogeneic Peripheral Blood Progenitor Cells

   • Ping Law, Thomas A. Lane

   Pages 51-77

5. Non-Myeloblative Induction of Mixed Hematopoietic Chimerism: Application to Transplantation Tolerance and Hematologic Malignancies in Experimental and Clinical Studies

   • Megan Sykes, Thomas R. Spitzer

   Pages 79-99

6. Combined Use of Auto-Grafting and Non-Myeloablative Allografting for the Treatment of Hematologic Malignancies and Metastatic Breast Cancer

   • Angelo M. Carella, Germana Beltrami, Enrica Lerma, Marina Cavaliere, Maria T. Corsetti

   Pages 101-112

7. Non-Myeloablative Hematopoietic Stem Cell Transplantation (NST) in the Treatment of Human Malignancies: From Animal Models to Clinical Practice

   • Avichai Shimoni, Arnon Nagler

   Pages 113-136

8. Non-Myeloablative Allogeneic Hematopoietic Transplantation and Induction of Graft-Versus-Malignancy

   • Issa Khouri, Sergio Giralt, Richard Champlin

   Pages 137-147

9. Outpatient Allografting in Hematologic Malignancies and Nonmalignant Disorders — Applying Lessons Learned in the Canine Model to Humans

   • Michael Maris, Rainer Storb

   Pages 149-175

10. Non-Myeloablative Transplants for Congenital Diseases

    • Jody Donahue, Ewa Carrier

    Pages 177-211

11. Back Matter

    Pages 213-216

    PDF

Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.

• Immunosuppression
• bone marrow
• cell
• hematopoietic stem cell
• hematopoietic stem cell transplantation
• immunotherapy
• lymphocytes
• morbidity
• mortality
• stem cell
• stem cell transplantation
• stem cells
• transplantation

• Blood and Marrow Transplantation Division, University of California, San Diego, USA

  Asad Bashey, Edward D. Ball

Policies and ethics